Free Practice Questions for Egyptian Board Hematology

Exam-style questions and explanations by OpenExamPrep.

✓ No registration✓ No credit card

100+ Questions

100% Free

Loading practice questions...

Same family resources

Explore More Egyptian Board Specialty Certifications (البورد المصري)

Continue into nearby exams from the same family. Each card keeps practice questions, study guides, flashcards, videos, and articles in one place.

Exam Review

Key Facts: Egyptian Board Hematology Exam

Law 12/2022

Governing Legislation (EHC)

Egyptian Health Council

3 Parts

Examination Stages (Part 1, 2 & Clinical OSCE)

EHC Regulations

Angoff / Hofstee

Written Standard Setting Method

EHC Assessment Framework

100 MCQs

Practice Bank Study Items

OpenExamPrep

The Egyptian Board in Hematology & Blood Transfusion is administered by the Egyptian Health Council under Law 12/2022 and Decree 3798/2023. It comprises Part 1 (basic sciences: hematopoiesis, molecular genetics, coagulation cascade physiology, blood group immunology; held March/August), Part 2 (clinical hematology: hemoglobinopathies, coagulopathies, hematologic malignancies, transfusion medicine, apheresis, bone marrow transplantation; held April/September), and Part 3 (annual clinical/morphological OSCE held Dec/Jan). This 100-question MCQ bank is an English-language study aid for Part 1 and Part 2 theoretical domains; Part 3 is a clinical/morphological OSCE and this bank does not substitute for clinical practice.

Sample Egyptian Board Hematology Practice Questions

Try these sample questions to review concepts for the Egyptian Board Hematology exam. Each question includes a detailed explanation. Start the interactive quiz above for the full 100+ question experience with AI tutoring.

1A flow cytometric analysis of human bone marrow is performed to isolate and characterize long-term repopulating hematopoietic stem cells (LT-HSCs). Which of the following immunophenotypic surface marker profiles definitively identifies this primitive, quiescent stem cell pool?

A.CD34+ CD38- Lin- CD90+ CD45RA-

B.CD34+ CD38+ Lin- CD90- CD45RA+

C.CD34- CD38+ Lin+ CD90+ CD45RA-

D.CD34+ CD38- Lin- CD90- CD45RA+

Explanation: Human long-term hematopoietic stem cells (LT-HSCs) reside within the CD34-positive, lineage-negative (Lin-) fraction and are specifically characterized by CD38 negativity, CD90 (Thy-1) positivity, and lack of CD45RA. Acquisition of CD38 or CD45RA reflects commitment toward multipotent progenitor or downstream lineage-restricted progenitor stages.

2A 48-year-old male with chronic kidney disease exhibits severe normocytic normochromic anemia. His hematologist considers the molecular cascade induced when recombinant erythropoietin binds its receptor (EpoR). Which of the following events is the critical proximal intracellular step following ligand-induced EpoR homodimer conformational change?

A.Recruitment of SMAD4 and direct transcription of globin gene enhancers

B.Transphosphorylation and activation of pre-associated JAK2 tyrosine kinase

C.Cleavage of membrane-bound Notch1 to release its nuclear intracellular domain

D.Direct GTP-binding and autophosphorylation of the c-Kit catalytic domain

Explanation: The erythropoietin receptor (EpoR) lacks intrinsic kinase activity and exists as a preformed homodimer. Binding of erythropoietin induces a conformational change that brings constitutive receptor-associated JAK2 tyrosine kinases into proximity, triggering JAK2 transphosphorylation and subsequent phosphorylation of specific tyrosine residues on the cytoplasmic tail of EpoR.

3In the regulation of megakaryopoiesis and platelet production, thrombopoietin (TPO) interacts with its specific cell-surface receptor, c-MPL (CD110). Which cellular mechanism is uniquely driven by TPO-MPL downstream signaling to yield functional, mature megakaryocytes?

A.Symmetric meiotic divisions producing haploid platelet precursor nuclei

B.Clonal chromosomal translocations generating polycistronic heavy chain transcripts

C.Endomitosis resulting in progressive cellular polyploidization up to 64N or 128N

D.Selective phagocytosis of basophilic erythroblasts within marrow erythroblastic islands

Explanation: Thrombopoietin signaling through c-MPL promotes megakaryocyte differentiation, survival, and endomitosis. Endomitosis is a specialized cell cycle variant where DNA replication occurs repeatedly without intervening mitosis or cytokinesis, generating polyploid megakaryocytes (typically 8N to 64N or higher) necessary for abundant platelet generation.

4A research investigator analyzes marrow biopsies from mice engineered with a conditional knockout of the basic leucine zipper transcription factor C/EBP-alpha (CCAAT/enhancer-binding protein alpha). Which specific phenotypic hematologic arrest is observed in these experimental models?

A.Arrest at the proerythroblast stage with severe congenital dyserythropoiesis

B.Complete absence of common lymphoid progenitors and mature B/T lymphocytes

C.Blockade of megakaryocyte fragmentation with severe isolated macrothrombocytopenia

D.Selective block in granulopoiesis at the common myeloid to granulocyte-monocyte progenitor transition

Explanation: C/EBP-alpha is an indispensable lineage-determining transcription factor required for the transition of common myeloid progenitors (CMPs) to granulocyte-monocyte progenitors (GMPs). Knockout of C/EBP-alpha causes a complete and selective arrest of neutrophilic granulopoiesis, leading to fatal congenital neutropenia, whereas erythropoiesis and megakaryopoiesis remain preserved.

5Hepcidin is the master systemic peptide hormone regulating human iron balance. Which of the following hepatic signaling mechanisms represents the principal physiological pathway inducing hepcidin transcription in response to systemic iron excess?

A.The BMP6-SMAD1/5/8 pathway coordinated by hemojuvelin, HFE, and transferrin receptor 2

B.The canonical Wnt-beta-catenin pathway mediated by low-density lipoprotein receptor-related protein 6

C.Direct nuclear translocation of NF-kappa-B upon cleavage of erythroferrone polymers

D.Constitutive activation of Notch-HES1 signaling driven by transferrin receptor 1 endocytosis

Explanation: Elevated circulating iron (diferric transferrin) and hepatic iron stores stimulate the bone morphogenetic protein 6 (BMP6) pathway. BMP6 binds its receptor complex in concert with the co-receptor hemojuvelin (HJV), HFE, and transferrin receptor 2 (TfR2), triggering phosphorylation of SMAD1/5/8, which associates with SMAD4 to activate hepcidin (HAMP) gene transcription.

6A 34-year-old female presents with severe microcytic hypochromic anemia and refractoriness to oral iron therapy. Genetic analysis identifies an autosomal dominant mutation in the SLC40A1 gene encoding ferroportin that prevents hepcidin binding without altering iron export. What laboratory and clinical presentation characterizes this condition?

A.Profound iron deficiency with elevated serum hepcidin and low macrophage iron stores

B.Systemic iron overload with elevated transferrin saturation and iron-loaded enterocytes and macrophages

C.Extreme hyperferritinemia with low-to-normal transferrin saturation and early macrophage iron loading

D.Aplastic anemia with marrow fat replacement and selective hypercupremia

Explanation: Gain-of-function SLC40A1 mutations that abolish hepcidin binding confer hepcidin resistance to ferroportin. Ferroportin remains continuously active on basolateral enterocyte membranes and reticuloendothelial macrophages, driving unrestrained iron efflux into plasma, high transferrin saturation, and parenchymal tissue iron overload clinically indistinguishable from classic HFE-associated hemochromatosis.

7At the post-transcriptional level, cellular iron homeostasis is precisely regulated by iron regulatory proteins (IRP1 and IRP2) binding to iron-responsive elements (IREs) on target mRNAs. When intracellular iron levels are critically depleted, what coordinate molecular events occur regarding ferritin and transferrin receptor 1 (TfR1) expression?

A.IRPs detach from 5' IRE of ferritin to boost translation, and detach from 3' IRE of TfR1 to trigger mRNA degradation

B.IRPs degrade ferritin mRNA via endonuclease cleavage and bind 5' IRE of TfR1 to accelerate ribosomal initiation

C.IRPs bind the 5' IRE of ferritin to repress translation, and bind 3' IREs of TfR1 to protect its mRNA from endonucleolytic degradation

D.IRPs translocate into the nucleus to hypermethylate the ferritin promoter and recruit RNA polymerase II to TfR1

Explanation: In iron-deficient cells, IRP1 and IRP2 assume high-affinity RNA-binding conformations. Binding of IRP to the single IRE in the 5' untranslated region (UTR) of ferritin mRNA sterically blocks ribosomal translation initiation, preventing futile iron storage. Concurrently, IRP binding to multiple IREs in the 3' UTR of TfR1 mRNA protects the transcript from endonuclease degradation, increasing TfR1 synthesis and cellular iron uptake.

8A 22-year-old medical student reviews erythroblast cellular iron acquisition. After circulating diferric transferrin binds to transferrin receptor 1 (TfR1 / CD71) on the erythroid membrane, which process is essential for releasing ferric iron from transferrin within the endosome?

A.Direct cleavage of transferrin peptide bonds by intra-endosomal granzyme B

B.Oxidation of ferrous iron to ferric iron by ceruloplasmin inside the endosome

C.Neutralization of endosomal pH via passive bicarbonate-chloride anion exchange

D.Proton pumping by vacuolar H+-ATPase to acidify the endosomal lumen to pH 5.5

Explanation: Upon clathrin-mediated endocytosis of the diferric transferrin-TfR1 complex, endosomal acidification to approximately pH 5.5 driven by an ATP-dependent vacuolar proton pump (V-ATPase) triggers a conformational change that releases ferric iron (Fe3+) from transferrin. The metalloreductase STEAP3 then reduces Fe3+ to Fe2+, which is transported into the cytosol via divalent metal transporter 1 (DMT1).

9A 55-year-old female undergoes total gastrectomy for gastric adenocarcinoma. Four years later, she develops severe megaloblastic anemia. Which sequential physiologic process is responsible for the dietary absorption of vitamin B12 (cobalamin) along the gastrointestinal tract?

A.Salivary haptocorrin binding in the stomach, degradation by pancreatic proteases in the duodenum, intrinsic factor binding, and cubam receptor-mediated endocytosis in the terminal ileum

B.Direct gastric intrinsic factor binding at pH 1.5, mucosal pinocytosis in the proximal jejunum, and portal transport bound to transcobalamin I

C.Gastric pepsin-mediated destruction of haptocorrin, bile salt conjugation in the jejunum, and passive paracellular absorption throughout the ascending colon

D.Gastric mucin complexation, brush-border cleavage by enteropeptidase in the duodenum, and active cotransport via sodium-dependent SGLT1 in the ileum

Explanation: Dietary cobalamin is released from animal proteins in the stomach and initially binds salivary haptocorrin (R-binder), protecting it from gastric acid. In the duodenum, pancreatic proteases degrade haptocorrin, allowing cobalamin to bind gastric parietal cell-derived intrinsic factor (IF). The IF-cobalamin complex travels intact to the terminal ileum, where it binds the cubam receptor complex (cubilin and amnionless) for receptor-mediated endocytosis.

10A 6-month-old infant with failure to thrive and severe macrocytic anemia is evaluated. Laboratory testing reveals normal serum total vitamin B12 levels, but genetic sequencing demonstrates a homozygous null mutation in the TCN2 gene. Which statement explains why normal total serum B12 levels co-exist with severe cellular B12 deficiency in transcobalamin II deficiency?

A.Transcobalamin II exclusively transports dietary folate, leaving cobalamin trapped in enterocytes

B.Transcobalamin I carries approximately 80% of circulating B12 but cannot deliver it to tissues, whereas transcobalamin II delivers the metabolically critical 20% to cells via CD320

C.Transcobalamin II is a nuclear chaperone that converts inactive methylcobalamin into active cyanocobalamin within mitochondria

D.Transcobalamin II functions as a serum scavenger that excretes toxic homocysteine conjugates into bile

Explanation: Approximately 70-80% of circulating cobalamin is bound to transcobalamin I (haptocorrin), which turns over slowly and lacks receptors for cellular tissue delivery. Transcobalamin II (TCN2) carries only 10-30% of total plasma B12, but this fraction constitutes the bioactive pool that undergoes rapid receptor-mediated endocytosis via the CD320 receptor in all proliferating tissues, including hematopoietic precursors.

About the Egyptian Board Hematology Exam

The Egyptian Board in Hematology & Blood Transfusion (أمراض الدم ونقل الدم) is the national postgraduate medical qualification awarded by the Egyptian Health Council (EHC), established pursuant to Law No. 12 of 2022 and its Executive Regulations (Decree No. 3798 of 2023), consolidating and replacing the former Egyptian Fellowship (الزمالة المصرية). The 4-year residency curriculum provides comprehensive competency-based training across benign hematology, regional hemoglobinopathies (beta-thalassemia, sickle cell disease), coagulation and thrombotic disorders, hematologic oncology (acute and chronic leukemias, lymphomas, multiple myeloma), blood bank management, apheresis, and hematopoietic stem cell transplantation. Important disclosure: Part Three is a dedicated practical and clinical OSCE examination covering peripheral smear and bone marrow aspirate slide interpretation and clinical cases; this 100-question multiple-choice question bank is an English-language study aid created to strengthen underlying theoretical knowledge, blood smear interpretation principles, coagulation profiles, and chemotherapy protocols for Part One and Part Two—it is not an OSCE simulation or a substitute for hands-on clinical and laboratory training.

Exam sponsor: Egyptian Health Council (EHC) — Egyptian Board (المجلس الصحي المصري — البورد المصري). The requirements and fees below concern the certification or admission exam, separate from our free practice resources.

Assessment

The Egyptian Board in Hematology & Blood Transfusion features a three-part assessment structure governed by the Egyptian Health Council: Part One is a written MCQ examination focusing on applied basic sciences (hematopoiesis, molecular genetics of hematology, coagulation cascade physiology, immunology of blood groups, and hematopathology) held twice yearly in March and August, enterable after 3 months of accredited training (maximum 6 attempts). Part Two is a written MCQ examination focusing on clinical hematology (red cell disorders including high-prevalence hemoglobinopathies such as thalassemia and sickle cell, coagulopathies, thrombosis, DOACs, HIT, hematologic malignancies, transfusion medicine, apheresis, and bone marrow transplantation) held twice yearly in April and September. Part Three is an annual clinical and practical examination held in December/January consisting of OSCE stations, peripheral smear and bone marrow aspirate slide interpretation, and clinical case discussions.

Time Limit

Varies by examination part

Passing Score

Set by psychometric standard-setting (Angoff/Hofstee method); no fixed percentage published

Exam / Certification Fees

Prescribed by Egyptian Health Council regulatory bylaws

Exam sponsor website

Reported exam pass rate: Determined by psychometric standard-setting per diet. Written examination cut scores (Part One and Part Two) are calculated using criterion-referenced standard-setting procedures (Angoff, Modified Angoff, or Hofstee). The Part Three clinical exam uses the Borderline Regression Method. There is no static passing percentage published. Exam sponsor website

Fees, eligibility, and exam policies can change. Confirm them with the exam sponsor before applying or paying.

Official sources

Our practice resources: topics covered

We aim to reflect publicly available exam outlines and topic information in our study resources. Coverage, format, and difficulty may differ from the actual exam, and we cannot guarantee that every detail is accurate or current. Confirm exam requirements, fees, and policies with the official exam sponsor.

25%

Part 1: Basic Sciences, Hematopoiesis & Coagulation Cascade

Hematopoietic stem cell differentiation, cytokine signaling (EPO, TPO, G-CSF), molecular genetics (JAK2, BCR-ABL1, FLT3, TP53), cell cycle kinetics, cell-based coagulation cascade, and RBC membrane and metabolic pathways.

20%

Part 1 & 2: Blood Group Immunology & Transfusion Medicine

ABO, RhD, and minor erythrocyte antigen systems, antibody identification, crossmatching, blood component processing, massive transfusion protocols, acute/delayed transfusion reactions, TRALI, apheresis modalities, and hemovigilance.

20%

Part 2: Red Cell Disorders & Hemoglobinopathies

Pathophysiology and clinical management of beta-thalassemia major/intermedia, alpha-thalassemia, sickle cell syndromes, nutritional anemias, autoimmune and microangiopathic hemolytic anemias, G6PD deficiency, and iron chelation.

15%

Part 2: Hemostasis, Coagulopathies & Thrombophilia

Hemophilia A and B, von Willebrand disease subtypes, disseminated intravascular coagulation, heparin-induced thrombocytopenia (HIT), DOAC dosing and reversal, antiphospholipid syndrome, and hereditary thrombophilias.

20%

Part 2: Hematologic Malignancies & Stem Cell Transplantation

Diagnostic criteria, cytogenetics, and treatment of AML, ALL, CML, CLL, MDS, myeloproliferative neoplasms, Hodgkin/non-Hodgkin lymphoma, multiple myeloma, autologous/allogeneic HSCT indications, GVHD, and CAR-T therapy.

Preparing for the Egyptian Board Hematology Exam

What You Need to Know

Passing score: Set by psychometric standard-setting (Angoff/Hofstee method); no fixed percentage published
Assessment: The Egyptian Board in Hematology & Blood Transfusion features a three-part assessment structure governed by the Egyptian Health Council: Part One is a written MCQ examination focusing on applied basic sciences (hematopoiesis, molecular genetics of hematology, coagulation cascade physiology, immunology of blood groups, and hematopathology) held twice yearly in March and August, enterable after 3 months of accredited training (maximum 6 attempts). Part Two is a written MCQ examination focusing on clinical hematology (red cell disorders including high-prevalence hemoglobinopathies such as thalassemia and sickle cell, coagulopathies, thrombosis, DOACs, HIT, hematologic malignancies, transfusion medicine, apheresis, and bone marrow transplantation) held twice yearly in April and September. Part Three is an annual clinical and practical examination held in December/January consisting of OSCE stations, peripheral smear and bone marrow aspirate slide interpretation, and clinical case discussions.
Time limit: Varies by examination part
Exam / certification fees: Prescribed by Egyptian Health Council regulatory bylaws Official sources

Using Our Practice Resources

Work through all 100 available questions
Review every answer and explanation
Track weak areas and revisit them
Use our AI tutor for tough concepts

Egyptian Board Hematology: Suggested Study Strategy

1Prioritize high-prevalence Egyptian hemoglobinopathies: understand beta-globin gene mutations, HPLC/electrophoresis interpretation, ineffective erythropoiesis, and MRI T2* iron chelation monitoring.

2Master the cell-based model of hemostasis and mixing study algorithms: know how to distinguish factor VIII inhibitors from lupus anticoagulants using incubated aPTT mixing tests and dilute Russell viper venom time (dRVVT).

3Thoroughly review acute leukemia cytogenetics and targeted therapies, including ATRA plus arsenic trioxide for APL, and BCR-ABL1 tyrosine kinase inhibitors for CML.

4Understand immunohematology and transfusion reactions: memorize the differences between TRALI (anti-HLA/HNA antibodies, bilateral non-cardiogenic infiltrates) and TACO (elevated BNP, fluid overload, responsive to diuretics).

5Consolidate multiple myeloma diagnostic criteria (SLiM-CRAB) and risk stratification, as well as the indications for autologous stem cell transplantation versus novel triplet/quadruplet induction regimens.

Frequently Asked Questions

What is the governing authority of the Egyptian Board in Hematology & Blood Transfusion?

The Egyptian Board (البورد المصري) is governed by the Egyptian Health Council (EHC / المجلس الصحي المصري), established under Law No. 12 of 2022 and its Executive Regulations (Prime Ministerial Decree No. 3798 of 2023). It is the sole national qualification authority unifying postgraduate medical training and certification in Egypt, replacing the former Egyptian Fellowship (الزمالة المصرية).

What is the examination structure of the Egyptian Board in Hematology?

The qualification features three distinct parts: Part One is a written MCQ examination covering applied basic sciences (hematopoiesis, molecular genetics of hematology, coagulation cascade physiology, blood group immunology, and hematopathology) held twice yearly in March and August. Part Two is a written MCQ examination focusing on clinical hematology, hemoglobinopathies, coagulopathies, malignancies, transfusion medicine, and BMT held twice yearly in April and September. Part Three is an annual clinical and practical examination held in December/January consisting of OSCE stations, peripheral smear and bone marrow aspirate slide interpretation, and clinical cases.

What standard-setting methodology is used to establish passing scores?

The Egyptian Health Council does not publish fixed percentage pass marks. Written examinations (Part One and Part Two) employ criterion-referenced psychometric standard-setting methodologies, specifically the Angoff, Modified Angoff, or Hofstee methods. Part Three clinical OSCE and morphology stations are evaluated using the Borderline Regression Method.

How many attempts are permitted for Part One?

Candidates may first sit for Part One after 3 months of accredited residency training. Under EHC regulations, candidates are permitted a maximum of six attempts to pass Part One before specialty progression review.

Does this question bank substitute for Part Three clinical and morphological training?

No. Part Three of the Egyptian Board is an in-person clinical and practical examination comprising Objective Structured Clinical Examination (OSCE) stations, peripheral smear and bone marrow aspirate slide interpretation, and clinical case discussions. This 100-question multiple-choice bank is an English-language theoretical study aid designed to reinforce core knowledge, blood smear interpretation principles, coagulation profiles, and chemotherapy protocols for Part One and Part Two; it is not an OSCE simulation or a substitute for hands-on clinical and laboratory training.

What official syllabus framework guides the examination?

The exam blueprint is aligned with the Egyptian Health Council reference framework and LMS training guidelines for Hematology and Blood Transfusion (أمراض الدم ونقل الدم), covering non-malignant hematology, hemoglobinopathies prevalent in Egypt and the Mediterranean, coagulopathies, hematologic oncology, transfusion medicine, and stem cell transplantation.

Free Practice Questions for Egyptian Board Hematology

Explore More Egyptian Board Specialty Certifications (البورد المصري)

Egyptian Board — Anesthesia (Part 1 & 2)

Egyptian Board — Cardiology (Part 1 & 2)

Egyptian Board — Clinical Infectious Diseases (Part 1 & 2)

Egyptian Board — Clinical Oncology (Part 1 & 2)

Egyptian Board — Clinical Pathology (Part 1 & 2)

Egyptian Board — Critical Care (Part 1 & 2)